Ming Hsieh Sells 2,227 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,227 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the sale, the chief executive officer now directly owns 703,711 shares in the company, valued at approximately $12,849,762.86. The trade was a 0.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Fulgent Genetics Price Performance

Shares of Fulgent Genetics stock opened at $18.07 on Friday. Fulgent Genetics, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $30.68. The business’s fifty day moving average is $19.86 and its two-hundred day moving average is $21.14.

Wall Street Analyst Weigh In

FLGT has been the topic of a number of recent research reports. StockNews.com lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday. Piper Sandler reduced their target price on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its stake in shares of Fulgent Genetics by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock worth $1,338,000 after purchasing an additional 637 shares during the period. Signaturefd LLC lifted its stake in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the period. Marquette Asset Management LLC lifted its stake in shares of Fulgent Genetics by 13.7% during the 3rd quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock worth $215,000 after purchasing an additional 1,191 shares during the period. Asset Dedication LLC purchased a new position in shares of Fulgent Genetics during the 2nd quarter worth $33,000. Finally, Centiva Capital LP increased its holdings in shares of Fulgent Genetics by 16.5% during the 3rd quarter. Centiva Capital LP now owns 12,538 shares of the company’s stock worth $272,000 after buying an additional 1,774 shares during the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.